Aurobindo Pharma registered a 22.8 per cent year-on-year rise in net profit at Rs. 780.6 crore for the first quarter ended June 2020.

The company's revenue from operations for the quarter stood at Rs. 5,924.8 crore, witnessed a growth of 8.8% over corresponding previous period.

The company's API revenue for the quarter was at Rs. 780.2 crore, an increase by 6.5% over corresponding previous period.

The company has received final approval for 10 ANDAs in Q1FY21.

Commenting on the company’s performance, N Govindarajan, managing director, Aurobindo Pharma, said: “Amidst challenging times, we have started the financial year by reporting a healthy performance. We have ensured the business continuity without compromising the safety and wellbeing of our employees. We are committed to adhere to quality standards by investing continuously and developing a differentiated product pipeline for a sustainable growth.”